Summary
McKesson Corporation (MCK) has filed an 8-K report detailing significant executive and governance changes. The most prominent update is the appointment of Brian S. Tyler as President and Chief Operating Officer, effective August 2, 2018. Mr. Tyler brings extensive experience within McKesson, having previously held leadership roles across various divisions, including McKesson Europe, North American Pharmaceutical Distribution and Services, and Corporate Strategy. His appointment is accompanied by an adjusted compensation package, reflecting his expanded responsibilities. Additionally, the company's Amended and Restated By-Laws have been updated, effective August 2, 2018. These amendments clarify the separation of Chief Executive Officer and President roles, define who can call special stockholder meetings, and delineate the authority of the CEO and President. These changes signal a restructuring of executive leadership and corporate governance. The filing also notes the departure of Nick Loporcaro, president of McKesson U.S. Pharmaceutical and Specialty Health, with Mr. Tyler temporarily overseeing these business segments.
Key Highlights
- 1Brian S. Tyler appointed President and Chief Operating Officer, effective August 2, 2018.
- 2Mr. Tyler has a long tenure with McKesson, holding various senior leadership positions.
- 3Mr. Tyler's compensation package has been revised to include a base salary of $1,000,000, a target annual bonus of 125% of salary, and long-term incentive awards.
- 4Amendments to McKesson's By-Laws will be effective August 2, 2018, clarifying executive roles and meeting procedures.
- 5The By-Law amendments will clarify that the CEO and President can be separate individuals.
- 6Nick Loporcaro, president of McKesson U.S. Pharmaceutical and Specialty Health, is leaving the company.
- 7Mr. Tyler will temporarily assume leadership of the U.S. Pharmaceutical and Specialty Health businesses.